reference/12091617

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12091617

Outgoing Links

Predicate	Object
contentType	Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	306
issn	0315-162X 1499-2752
issueIdentifier	2
pageRange	298-306
publicationName	The Journal of Rheumatology
startingPage	298
bibliographicCitation	Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial. J Rheumatol. 2016 Feb;43(2):298–306. doi: 10.3899/jrheum.150712. PMID: 26669912.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9eb35d5eb088de2d0ea27595740e32f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d66fba813b0c75130c6761af78fe3cf9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4658-1093 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4034d6a9b35e2495d32586e3ba44c378 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4bd3d22df0ada08ac77ed12b900f9f7c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_09433bc37715d2867671e817dd531e44 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db95d07ad677920b505ac9a5ede6cb48 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b769f9d7a6377321401875951b5b368 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55d937e29f36cd581d4185ca239bee9f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7dc13e28c1be3a48d8cd148b329fb831 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb5e269c1afd2c1ce545f50e6a625df8
date	2015-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3899/jrheum.150712 https://pubmed.ncbi.nlm.nih.gov/26669912
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5243 https://portal.issn.org/resource/ISSN/1499-2752 https://portal.issn.org/resource/ISSN/0315-162X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial
discusses	http://id.nlm.nih.gov/mesh/M0027742 http://id.nlm.nih.gov/mesh/M0521570 http://id.nlm.nih.gov/mesh/M0013595 http://id.nlm.nih.gov/mesh/M0001357
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000911Q000627 http://id.nlm.nih.gov/mesh/D018501Q000627 http://id.nlm.nih.gov/mesh/D008727Q000627 http://id.nlm.nih.gov/mesh/D001172Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D000911Q000008 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D000911Q000009 http://id.nlm.nih.gov/mesh/D018501Q000008 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D018501Q000009 http://id.nlm.nih.gov/mesh/D004359 http://id.nlm.nih.gov/mesh/D007279
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6969 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_a7939d043567ee90a9f1febb314e563d http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID126941 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8596 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8214

Total number of triples: 53.